This CPB is revised to state that Fibryga (human fibrinogen concentrate) is considered medically necessary for the treatment of acute bleeding episodes in persons with congenital fibrinogen deficiency including afibrinogenemia and hypofibrinogenemia when the diagnosis of congenital fibrinogen deficiency has been confirmed by blood coagulation testing. The title of this CPB has been changed to "Human Fibrinogen Concentrate (RiaSTAP and Fibryga)."